Current Pharmaceutical Design - Volume 6, Issue 11, 2000

A variety of radiopharmaceuticals have been introduced for the internal therapy of malignant and inflammatory lesions in nuclear medicine. In order to destroy the disseased tissues radionuclides with high linear energy transfer (LET) such as beta, alpha, Auger or low energy conversion electron emitters are needed. The range of beta particles is in mms so they are effective for large tumors. The range of alpha particles i Read More

Development of peptides and amino acids labeled with single photon gamma emitters has promoted a large number of investigations in nuclear medicine especially for tumor imaging. Radiolabeled peptides have several advantages over antibodies mainly related to immunogenicity and size. Tumor localization and total body clearance of peptides are more rapid compared to antibodies. Recently, several somatostatin analogu Read More

Nowadays, the scientists from different disciplines have focused their attentions to new anticancer drug design for cancer chemotherapy. An effective anticancer drug should ensure the selective drug incorporation into the targeted tumor cells without principally incorporation into the normal cells. So, the targeted tumor cells can selectively be damaged by the cytotoxic effectiveness of the drug. The basic principles of Read More

In vivo imaging techniques like positron emission tomography (PET) and single photon emission computed tomography (SPECT) offer the possibility to monitor human central nicotinic acetylcholine receptors (nAChRs) in a variety of central nervous system disorders. In the past, the only available PET radiotracer for imaging nAChRs in the human brain, ( 11 C)-(-)-nicotine, suffered from a spectrum of not suitable properties for in vi Read More

Many radiopharmaceuticals have been introduced for the scintigraphic demonstration of infectious and inflammatory lesions and some of them are currently in clinical use. They can be classified into two major categories according to their specificity. Specific radiopharmaceuticals include in vitro labeled leukocytes, radio-labelled monoclonal antibodies, and receptor specific small proteins and peptides. Nonspecific radiopharmace Read More

The influence of drugs on the labeling of red blood cells and plasma proteins with 99mTc has been reported. Any drug, which alters the labeling of the tracer, could be expected to modify the disposition of the radiopharmaceuticals. Red blood cells (RBC) labeled with technetium-99m (99mTc) are used for several evalua-tions in nuclear medicine. We have evaluated the effect of Thuya occidentalis, Peumus boldus and Nicotiana Read More